Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.70 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6637138 | 1.00 | AGTR1 (1.00) | AGTR1ABCC3ABCC2 | |
| SCHEMBL6638307 | 0.95 | AGTR1 (0.91) | AGTR1 | |
| SCHEMBL6638300 | 0.95 | AGTR1 (0.91) | AGTR1 | |
| SCHEMBL9126955 | 0.92 | AGTR1 (0.85) | AGTR1 | |
| SCHEMBL9126960 | 0.92 | AGTR1 (0.85) | AGTR1 | |
| SCHEMBL6963946 | 0.90 | AGTR1 (0.82) | AGTR1ABCC3ABCC2 | |
| SCHEMBL6963959 | 0.90 | AGTR1 (0.82) | AGTR1ABCC3ABCC2 | |
| SCHEMBL6636932 | 0.89 | AGTR1 (0.80) | AGTR1ABCC3ABCC2 | |
| SCHEMBL6636924 | 0.89 | AGTR1 (0.80) | AGTR1ABCC3ABCC2 | |
| SCHEMBL9593529 | 0.86 | AGTR1 (0.75) | AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0561977-B1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF HEMORRAGIC STROKE | SMITHKLINE BEECHAM PLC (GB) | 2004-05-26 | — | — | EP | claimed |
| EP-0724387-B1 | ANGIOTENSION II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | claimed |
| US-5656650-A | TREATING HYPERTENSION | SMITHKLINE BEECHAM CORP. | 1997-08-12 | — | — | US | claimed |
| US-5418250-A | Hypotensive | SMITHKLINE BEECHAM CORPORATION (US) | 1995-05-23 | — | — | US | claimed |
| EP-0641203-A1 | IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-03-08 | — | — | EP | claimed |
| EP-0641203-A4 | IMIDAZOLYL-ALKENOIC ACIDS. | SMITHKLINE BEECHAM CORP (US) | 1994-06-09 | — | — | EP | claimed |
| EP-0565634-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-20 | — | — | EP | claimed |
| WO-1993006828-A1 | MEDICAMENT FOR THE TREATMENT OF ANXIETY | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-15 | — | — | WO | claimed |
| WO-1993003722-A1 | IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-04 | — | — | WO | claimed |
| WO-1992010097-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-25 | — | — | WO | claimed |
| EP-0561977-B1 | USE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN THE TREATMENT OF HEMORRAGIC STROKE | SMITHKLINE BEECHAM PLC (GB) | 2004-05-26 | — | — | EP | disclosed |
| EP-0724387-B1 | ANGIOTENSION II RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CHRONIC ANTI-INFLAMMATORY DISEASES | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20030004201-A1 | Medicament | SMITHKLINE BEECHAM P.L.C. | 2003-01-02 | — | — | US | disclosed |
| EP-0565634-B1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORP (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5656650-A | TREATING HYPERTENSION | SMITHKLINE BEECHAM CORP. | 1997-08-12 | — | — | US | disclosed |
| EP-0565634-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-10-20 | — | — | EP | disclosed |
| WO-1993006828-A1 | MEDICAMENT FOR THE TREATMENT OF ANXIETY | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-15 | — | — | WO | disclosed |
| WO-1993003722-A1 | IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5185351-A | Hypotensive agents; for treatment of congestive heart failure, renal failure and glaucoma | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-09 | — | — | US | disclosed |
| WO-1992010097-A1 | ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004201-A1 | Medicament | AGTR2, AGTR1, ACE | AGTR1 2/4885ABCC3 860/4885ABCC2 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.